Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 3
Submit an article Journal homepage
166
Views
7
CrossRef citations to date
0
Altmetric
Original Articles: Research

Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia

Wen XuDepartment of Immunology, Harbin Medical University, Harbin, People’s Republic of China; Correspondence[email protected]
View further author information
,
Xiaoxia LiDepartment of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China; View further author information
,
Lina QuanDepartment of Hematology, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of ChinaView further author information
,
Jiying YaoDepartment of Immunology, Harbin Medical University, Harbin, People’s Republic of China; View further author information
,
Guannan MuDepartment of Immunology, Harbin Medical University, Harbin, People’s Republic of China; View further author information
,
Jingjie GuoDepartment of Immunology, Harbin Medical University, Harbin, People’s Republic of China; View further author information
&
Yitong WangDepartment of Immunology, Harbin Medical University, Harbin, People’s Republic of China; View further author information
 show all
Pages 650-659 | Received 25 Jan 2017, Accepted 17 Jun 2017, Published online: 06 Jul 2017

References

  • Zhang TD, Chen GQ, Wang ZG, et al. Arsenic trioxide, a therapeutic agent for APL. Oncogene. 2001;20:7146–7153.
  • Zhu J, Koken HM, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implication for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA. 1997;94:3978–3983.
  • Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052–1061.
  • Jing Y, Dai J, Chaimers-Redman RME, et al. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102–2111.
  • Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999;59:776–780.
  • Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000;96:1525–1530.
  • Ablain J, de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 2011;117:5795–5802.
  • Zheng X, Seshire A, Ruster B, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica. 2007;92:323–331.
  • Ustun C, Miller JS, Munn DH, et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118:5084–5095.
  • Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematologic relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. JCO. 2007;25:4938–4945.
  • Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116:2411–2419.
  • Godder KT, Henslee-Downey PJ, Mehta J, et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007;39:751–757.
  • Zhou Q, Munger ME, Highfill SL, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010;116:2484–2493.
  • Curti A, Pandolfi S, Valzasina B, et al. Modulation of tryptophan catabolism by human leukemia cells results in the conversion of CD25– into CD25+ T regulatory cells. Blood. 2007;109:2871–2877.
  • Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–949.
  • Alvaro T, Lejeune M, Salvadó MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467–1473.
  • Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer. Adv Cancer Res. 2010;107:57–117.
  • Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345–3353.
  • Zhou Q, Bucher C, Munger ME, et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009;114:3793–3802.
  • Deaglio S, Canella D, Baj G, et al. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. Leuk Res. 2001;25:227–235.
  • Baj G, Arnulfo A, Deaglio S, et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat. 2002;73:61–73.
  • Thomas-Schoemann A, Batteux F, Mongaret C, et al. Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. J Immunol. 2012;189:5171–5177.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.